Tonghua Dongbao Receives NMPA Approval for THDBH151 Clinical Study in Gout and Hyperuricemia

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its dual-targeted drug candidate THDBH151 in gout and hyperuricemia. This marks a significant step forward in the development of innovative treatments for these conditions.

Existing Therapies and THDBH151 Mechanism
Existing gout therapies include xanthine oxidase inhibitors (allopurinol, febuxostat) and URAT1 inhibitors (benzbromarone, lesinurad), both of which have room for improvement in terms of safety and efficacy. THDBH151, however, offers a dual-targeted approach by inhibiting xanthine oxidase (XO) to reduce the production of uric acid from the source and inhibiting the reabsorption of uric acid by the renal tubular URAT1 transporter to accelerate its excretion.

Clinical Benefits and Future Prospects
By balancing the role of XO/URAT1 in the process of reducing uric acid, THDBH151 tablets can improve efficacy and reduce side effects, significantly improving patient compliance. The NMPA’s approval to initiate clinical studies positions Tonghua Dongbao to further explore the potential benefits of THDBH151, addressing significant unmet medical needs in the treatment of gout and hyperuricemia.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry